Evidence map›Paper›PMID 41523451›Full record

ArticleCureus2025

Ozoralizumab-Induced Multifocal Demyelinating Neuropathy in a Patient With Rheumatoid Arthritis.

Yuya Ikegawa, Yuichi Hamada, Naoki Hayakawa, Kazuto Nishinaka

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yuya IkegawaNeurology, Sumitomo Hospital, Osaka, JPN.
Yuichi HamadaNeurology, Sumitomo Hospital, Osaka, JPN.
Naoki HayakawaNeurology, Sumitomo Hospital, Osaka, JPN.
Kazuto NishinakaNeurology, Sumitomo Hospital, Osaka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor-α (TNF-α) inhibitors can induce demyelinating polyneuropathy, but this has not been reported with ozoralizumab. We report a case of a 57-year-old male with rheumatoid arthritis who developed paresthesia in the left hand, bilateral wrist drop, and reduced grip strength after starting ozoralizumab. Nerve conduction studies showed bilateral radial nerve conduction blocks consistent with demyelination. Symptoms persisted after discontinuation of ozoralizumab but resolved after two courses of intravenous immunoglobulin therapy, with complete clinical and electrophysiological recovery. This case suggests that ozoralizumab may trigger multifocal demyelinating neuropathy.

Indexed as

demyelinating diseasesozoralizumabperipheral nervous system diseasesrheumatoid arthritistumor necrosis factor inhibitors

Identifiers

PMID41523451
PMCPMC12782720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.